SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the ...

Guidelines statement on biosimilars was revised to include any appropriate biosimilar for a therapy vs focusing on rituximab.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Rituxan ...

With the Food and Drug Administration’s approval of Ruxience, a biosimilar to Rituxan, patients with certain types of non-Hodgkin lymphoma and chronic lymphocytic leukemia may have improved access to ...

Golcadomide, a first-in-class, oral CELMoD (cereblon E3 ligase modulator), has shown compelling activity as a monotherapy and ...

For patients presenting with moderate to severe pemphigus, the choice of initial therapy has been distilled to a single agent: rituximab. This drug is more rapidly effective, more likely to provide ...

The addition of epcoritamab to standard therapy significantly improved PFS for patients with relapsed or refractory ...

The treatment regimen achieved a 100% overall response rate, with 95% of patients reaching complete response after brexucabtagene autoleucel infusion. Safety concerns included cytokine release ...

THOUSAND OAKS, Calif., June 6, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan® ...

When you have lupus, your body’s immune system turns against your healthy tissue and organs, such as skin, joints, brain, heart, lungs, and kidneys. One of the newer treatments for lupus, called ...